Cellular and regenerative medicine introduces a shift in healthcare – the promise of using the body’s own abilities to heal. Innovation in this area is driving dramatic change in the prevention, treatment and cure of diseases and disorders.
The nature of cell and gene therapies (CGT) requires rethinking traditional business models and operations. Geographically dispersed networks of cell collection, processing, manufacturing, and treatment facilities, along with responsibility for Chain of Integrity/Chain of Custody (CoI/CoC) create new demands on the operations network.
Converge understands the risks, complexity, and uncertainty for CGT companies moving from preclinical to clinical development, preparing for commercial product launch, and scaling operations. We extend our clients’ reach, close knowledge/skill gaps, and shorten the time required to complete crucial initiatives.